Study:
S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma
Rationale:
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune
system in different ways and stop cancer cells from growing. It may also stop the growth of
cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving bortezomib together with thalidomide and
dexamethasone may kill more cancer cells.
Purpose:
This phase II trial is studying how well giving bortezomib together with
thalidomide and dexamethasone works in treating patients with relapsed or refractory
multiple myeloma.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Multiple Myeloma |
Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide |
Phase 2 |
Verified by
Southwest Oncology Group
March, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00124579
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Gordan Srkalovic, MD, PhD., Principal Investigator
Mohamad A. Hussein, MD., Principal Investigator